From the Department of Radiology (F.C.C., A.M.M., A.M.d.A., V.C.d.P.R., G.G.C.) and Division of Urology (A.A.A., M.S.), University of São Paulo Medical School, Av. Dr. Enéas Carvalho de Aguiar, 255, São Paulo, SP 05403-000, Brazil.
Radiology. 2020 Aug;296(2):444-451. doi: 10.1148/radiol.2020191249. Epub 2020 Jun 2.
Background Long-term experience with prostatic artery embolization (PAE) for benign prostatic hyperplasia remains limited. Purpose To evaluate the efficacy, safety, and long-term results of PAE for benign prostatic hyperplasia. Materials and Methods This retrospective single-center study was conducted from June 2008 to June 2018 in patients with moderate to severe benign prostatic hyperplasia-related symptoms. International Prostate Symptom Score (IPSS), quality-of-life score, maximum urinary flow rate, postvoid residual volume, prostate-specific antigen (PSA), and prostate volume were assessed. PAE was performed with 100-500-μm embolic microspheres. Mixed-model analysis of variance and Kaplan-Meyer method was accessed, as appropriate. Results A total of 317 consecutive men (mean age ± standard deviation, 65 years ± 8) were treated. Follow-up ranged from 3 months to 96 months (mean, 27 months). Bilateral and unilateral PAE was performed in 298 (94%) and 19 (6%) men, respectively. Early clinical failure occurred in six (1.9%) and symptom recurrence in 72 (23%) men at a median follow-up of 72 months. Mean maximum improvement was as follows: IPSS, 16 points ± 7; quality-of-life score, 4 points ± 1; prostatic volume reduction, 39 cm ± 39 (39% ± 29); maximum urinary flow rate, 6 mL/sec ± 10 (155% ± 293); and postvoid residual volume, 70 mL ± 121 (48% ± 81) ( < .05 for all). Unilateral PAE was associated with higher recurrence (42% vs 21%; = .04). Baseline PSA was inversely related with recurrence (hazard ratio, 0.9 per nanograms per milliliter of PSA; 95% confidence interval [CI], 0.8, 0.9; < .001). Embolization with combined particle sizes (100-500 μm) did not relate to symptom recurrence (hazard ratio, 0.4; 95% CI: 0.2, 1.1 for 100-500-μm group vs 300-500-μm group and hazard ratio, 0.4; 95% CI: 0.1, 1.5 for 100-500-μm group vs 100-300-μm group; = .19).None of the patients presented with urinary incontinence or erectile dysfunction. Conclusion Prostatic artery embolization was a safe and effective procedure for benign prostatic hyperplasia with good long-term results for lower urinary tract symptoms. © RSNA, 2020
前列腺动脉栓塞术(PAE)治疗良性前列腺增生的长期经验仍然有限。目的:评估 PAE 治疗良性前列腺增生的疗效、安全性和长期结果。材料与方法:本回顾性单中心研究于 2008 年 6 月至 2018 年 6 月在有中度至重度良性前列腺增生相关症状的患者中进行。评估国际前列腺症状评分(IPSS)、生活质量评分、最大尿流率、剩余尿量、前列腺特异性抗原(PSA)和前列腺体积。使用 100-500μm 栓塞微球进行 PAE。适当情况下采用混合模型方差分析和 Kaplan-Meier 方法。结果:共治疗了 317 例连续男性患者(平均年龄±标准差,65 岁±8 岁)。随访时间为 3 个月至 96 个月(平均 27 个月)。298 例(94%)和 19 例(6%)患者分别行双侧和单侧 PAE。中位随访 72 个月时,6 例(1.9%)出现早期临床失败,72 例(23%)出现症状复发。最大改善的平均情况如下:IPSS,16 分±7;生活质量评分,4 分±1;前列腺体积减少,39cm±39(39%±29);最大尿流率,6ml/sec±10(155%±293);剩余尿量,70ml±121(48%±81)(所有 P<.05)。单侧 PAE 与更高的复发率相关(42%比 21%;P=.04)。基线 PSA 与复发呈负相关(风险比,每纳克/毫升 PSA 降低 0.9;95%置信区间[CI],0.8,0.9;P<.001)。采用 100-500μm 混合粒径的栓塞与症状复发无关(风险比,100-500μm 组与 300-500μm 组相比为 0.4;95%CI:0.2,1.1;100-500μm 组与 100-300μm 组相比为 0.4;95%CI:0.1,1.5;P=.19)。无患者出现尿失禁或勃起功能障碍。结论:前列腺动脉栓塞术是一种安全有效的治疗良性前列腺增生的方法,对下尿路症状有良好的长期疗效。